The drug didn’t cause serious side effects in these patients, even after a year of daily injections.
Scientific Claim
Tesamorelin (2 mg subcutaneous daily) is well tolerated in HIV-infected adults on antiretroviral therapy with abdominal fat accumulation over 12 months, with no major safety signals reported.
Original Statement
“The drug was well tolerated.”
Evidence Quality Assessment
Claim Status
understated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
While 'well tolerated' is a general statement, the study collected safety data (e.g., glucose, IGF-I) and reported no significant adverse events, justifying stronger definitive language.
More Accurate Statement
“Tesamorelin (2 mg subcutaneous daily) is well tolerated in HIV-infected adults on antiretroviral therapy with abdominal fat accumulation over 12 months, with no clinically significant adverse events or laboratory abnormalities reported.”
Evidence from Studies
Supporting (1)
Unknown Title
The study found that taking tesamorelin daily for a year helped reduce belly fat in HIV patients without causing serious side effects, so it’s safe to use as described.